A secondary heart attack could be prevented by replacing 30 minutes of sedentary behavior with light-intensity or moderate-to ...

An estimated 32 million people globally have heart failure with reduced ejection fraction, a condition where the lower left ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Cleveland Clinic experts reveals what's behind "Ozempic face," and list the semaglutide-associated symptoms that can call for medical attention.

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...